PRLD (Prelude Therapeutics Incorporated) Stock Analysis - Hedge Fund Holdings
Prelude Therapeutics Incorporated (PRLD) is a publicly traded Healthcare sector company. As of May 21, 2026, PRLD trades at $4.51 with a market cap of $345.66M and a P/E ratio of -4.37. PRLD moved +5.50% today. Year to date, PRLD is +84.43%; over the trailing twelve months it is +358.25%. Its 52-week range spans $0.61 to $5.54. Analyst consensus is strong buy with an average price target of $7.67. Rallies surfaces PRLD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns PRLD stock?
Hedge funds tracked by Rallies that own PRLD include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Prelude Therapeutics Incorporated.
PRLD Key Metrics
Key financial metrics for PRLD
Metric
Value
Price
$4.51
Market Cap
$345.66M
P/E Ratio
-4.37
EPS
$-1.00
Dividend Yield
0.00%
52-Week High
$5.54
52-Week Low
$0.61
Volume
27
Avg Volume
0
Revenue (TTM)
$16.72M
Net Income
$-77.80M
Gross Margin
0.00%
Top Hedge Funds Holding PRLD
Orbimed Advisors holds 10.91M shares of PRLD, changed +0.00% as of Mar 31, 2026.
Hedge funds tracked by Rallies that own PRLD include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Prelude Therapeutics Incorporated.
Does Rallies show 13F holders for PRLD?
Yes. Rallies tracks hedge fund and 13F ownership data for PRLD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PRLD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PRLD. It does not provide personalized investment advice.
